Gynecologic Cancers

Updates in ovarian cancer include multiple fast track designations and breakthrough therapy status for new drugs in the clinical space.

Chemoradiotherapy led to OS and RFS benefit in high-risk patients with chemoradiotherapy vs radiotherapy alone.

The FDA granted JSKN003 breakthrough therapy status for gynecologic cancers based on data from the phase 1 JSKN003-101 and phase 1/2 JSKN003-102 trials.

Hormone replacement therapy was associated with a lower risk of developing BRCA1- or BRCA2-mutated breast cancer among those already at higher risk.

Nurses play a key role in helping patients with cervical cancer weigh the risks and benefits of radiation and concurrent chemotherapy.

Pembrolizumab plus paclitaxel with or without bevacizumab boosted survival in patients with platinum-resistant, recurrent ovarian cancer.

Integrating PRO tools in survivorship care may help oncology nurses address ongoing emotional and physical needs of ovarian cancer survivors.

After undergoing EBRT and brachytherapy at 14, an AYA cancer survivor discusses her experience with a rare vaginal cancer and Turner syndrome.

Subcutaneous pembrolizumab has been approved across all indications, cutting chair and administration times with a median injection time of 2 minutes.

Read an advanced practice nurse's tips for treating patients with endometrial cancer with durvalumab.

Relacorilant’s new drug application for platinum-resistant ovarian cancer has been accepted by the FDA.

Understanding which patients may benefit from CLDN6-targeting immunotherapy and recognizing potential adverse effects is essential for oncology nurses.

The investigational ADC rinatabart sesutecan was given breakthrough therapy designation for use in patients with recurrent/progressive endometrial cancer.

The addition of avutometinib to defactinib showed promising safety and efficacy for patients with low-grade serous ovarian cancer.

In TP53 wild-type advanced or recurrent endometrial cancer, selinexor improved multiple time-to-event outcomes vs placebo.

Oncology nurses can help patients understand this novel mechanism of action and its potential as a treatment option.

The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.

Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking adavosertib.

Approvals in oncology during April included treatments for breast cancer, colorectal cancer, and more.

Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with cancer.

The PRECURSOR intervention appeared feasible/acceptable, suggesting a need for patient-centered conversation in incurable gynecologic cancer treatment.

Oncology nurses can support patients facing financial toxicity by offering guidance on available resources and providing emotional support.

The FDA approved bevacizumab-nwgd across several gastrointestinal, gynecological, brain, and lung cancer types.